MA43162A - Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton - Google Patents
Inhibiteurs de type imidazopyrazine de tyrosine kinase de brutonInfo
- Publication number
- MA43162A MA43162A MA043162A MA43162A MA43162A MA 43162 A MA43162 A MA 43162A MA 043162 A MA043162 A MA 043162A MA 43162 A MA43162 A MA 43162A MA 43162 A MA43162 A MA 43162A
- Authority
- MA
- Morocco
- Prior art keywords
- imidazopyrazine
- inhibitors
- tyrosine kinase
- bruton tyrosine
- bruton
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562252420P | 2015-11-06 | 2015-11-06 | |
US201562261228P | 2015-11-30 | 2015-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43162A true MA43162A (fr) | 2018-09-12 |
Family
ID=57286764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043162A MA43162A (fr) | 2015-11-06 | 2016-11-04 | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton |
Country Status (6)
Country | Link |
---|---|
US (2) | US10736893B2 (fr) |
EP (2) | EP3371189A1 (fr) |
JP (1) | JP6890602B2 (fr) |
CN (1) | CN108602827B (fr) |
MA (1) | MA43162A (fr) |
WO (1) | WO2017077507A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3371189A1 (fr) * | 2015-11-06 | 2018-09-12 | Acerta Pharma B.V. | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton |
JP6715357B2 (ja) * | 2016-06-30 | 2020-07-01 | 杭州三因泰医薬科技有限公司Hangzhou Sanyintai Pharmaceutical Technology Co., Ltd. | イミダゾピリジンアミンフェニル誘導体およびその使用 |
CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
AU2018237123B2 (en) * | 2017-03-22 | 2022-08-04 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
US10800787B2 (en) | 2017-04-20 | 2020-10-13 | Apotex Inc. | Process for the preparation of acalabrutinib |
KR102384924B1 (ko) * | 2017-07-12 | 2022-04-08 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
WO2019013562A1 (fr) * | 2017-07-12 | 2019-01-17 | 주식회사 대웅제약 | Nouveau dérivé de 1h-pyrazolopyridine et composition pharmaceutique le contenant |
CN109836416B (zh) * | 2017-11-27 | 2023-02-03 | 苏州鹏旭医药科技有限公司 | 一种化合物的制备方法 |
US11161851B2 (en) * | 2017-11-06 | 2021-11-02 | Suzhou Pengxu Pharmatech Co. Ltd. | Processes to produce acalabrutinib |
CN108129483B (zh) * | 2018-01-26 | 2019-06-04 | 成都施贝康生物医药科技有限公司 | 一种btk抑制剂及其应用 |
CN108250186B (zh) * | 2018-02-07 | 2020-01-14 | 杭州科巢生物科技有限公司 | Acalabrutinib及其中间体的合成方法 |
KR102106821B1 (ko) | 2018-04-27 | 2020-05-06 | 재단법인대구경북과학기술원 | 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
CN109053780B (zh) * | 2018-07-05 | 2020-09-29 | 浙江合聚生物医药有限公司 | 一种抗肿瘤药物Acalabrutinib关键中间体的制备方法 |
JP7439095B2 (ja) * | 2018-08-29 | 2024-02-27 | アセルタ・ファーマ・ベスローテン・フェンノートシャップ | 4-{8-アミノ-3-[(2S)-1-(ブタ-2-イノイル)-ピロリジン-2-イル]イミダゾ[1,5-a]-ピラジン-1-イル}N-(ピリジン-2-イル)-ベンズアミドの調製のためのプロセス |
CN112805287B (zh) * | 2018-09-14 | 2023-01-24 | 正大天晴药业集团股份有限公司 | 含有呋喃并[3,4-b]吡咯的BTK抑制剂 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020225831A1 (fr) * | 2019-05-09 | 2020-11-12 | Msn Laboratories Private Limited, R&D Center | Procédé amélioré pour la préparation de 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide |
CN113993871B (zh) * | 2019-07-12 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 含有5-氮杂螺庚烷的btk抑制剂 |
WO2021089791A1 (fr) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
DE60235013D1 (de) | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
WO2007147001A2 (fr) | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Formulations lyophilisées d'anticorps anti-egfr |
US7894450B2 (en) | 2007-12-31 | 2011-02-22 | Nortel Network, Ltd. | Implementation of VPNs over a link state protocol controlled ethernet network |
MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
EP2548877A1 (fr) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK |
ES2950569T3 (es) * | 2011-07-19 | 2023-10-11 | Merck Sharp & Dohme | (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk |
WO2015057992A1 (fr) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Inhibiteurs btk pour la mobilisation hématopoïétique |
WO2015110923A2 (fr) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk |
TW201618774A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | 使用btk抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法 |
EP3371189A1 (fr) * | 2015-11-06 | 2018-09-12 | Acerta Pharma B.V. | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton |
-
2016
- 2016-11-04 EP EP16794751.4A patent/EP3371189A1/fr not_active Withdrawn
- 2016-11-04 WO PCT/IB2016/056661 patent/WO2017077507A1/fr active Application Filing
- 2016-11-04 CN CN201680077913.0A patent/CN108602827B/zh active Active
- 2016-11-04 EP EP21151227.2A patent/EP3865485A1/fr not_active Withdrawn
- 2016-11-04 MA MA043162A patent/MA43162A/fr unknown
- 2016-11-04 JP JP2018541596A patent/JP6890602B2/ja active Active
- 2016-11-04 US US15/773,846 patent/US10736893B2/en active Active
-
2020
- 2020-06-30 US US16/917,222 patent/US11110088B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108602827B (zh) | 2021-08-20 |
US11110088B2 (en) | 2021-09-07 |
US10736893B2 (en) | 2020-08-11 |
CN108602827A (zh) | 2018-09-28 |
EP3865485A1 (fr) | 2021-08-18 |
EP3371189A1 (fr) | 2018-09-12 |
WO2017077507A1 (fr) | 2017-05-11 |
JP2018536705A (ja) | 2018-12-13 |
US20200330461A1 (en) | 2020-10-22 |
US20180318297A1 (en) | 2018-11-08 |
JP6890602B2 (ja) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43162A (fr) | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton | |
IL279258B (en) | tyrosine kinase inhibitors | |
MA42623A (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
DK3497086T3 (da) | Aminopyrimidin-SSAO-inhibitorer | |
CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
MA52814A (fr) | Inhibiteurs de bromodomaine | |
BR112017002232A2 (pt) | combinações de inibidor de tirosina quinase de bruton e usos das mesmas | |
BR112017018413A2 (pt) | tratamento de pancreatite | |
DK3383314T3 (da) | Teksturerede overflader til implantater | |
DK3290418T3 (da) | Janus Kinase (JAK)-hæmmere | |
MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
BR112017022691A2 (pt) | inibidor de bromodomínio. | |
MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
DK3288931T4 (da) | Visse proteinkinaseinhibitorer | |
ZA201808238B (en) | Certain protein kinase inhibitors | |
DK3283776T3 (da) | Vippedyvel | |
MA44607A (fr) | Inhibiteurs de kinase | |
DOS2016000086S (es) | Bandeja | |
DK3322724T3 (da) | Il-26 inhibitorer | |
DK3436047T3 (da) | Duale Ace-C-Domain-inhibitorer | |
TH1501006103A (th) | สารยับยั้งโปรตีนไคเนส | |
UA33368S (uk) | Лоток | |
CL2015003098S1 (es) | Bandeja | |
UA32696S (uk) | Вкладиш вала колінчастого |